Molybdenum Requirement of Leguminous Plants Supplied with Fixed Nitrogen.

W. R. Meagher,C. Johnson,P. Stout

DOI: https://doi.org/10.1104/PP.27.2.223

IF: 7.4

1952-04-01

PLANT PHYSIOLOGY

Abstract:

What problem does this paper attempt to address?

Comparison of Endovascular Treatment for Middle Cerebral Artery Aneurysm with a Low-Profile Visualized Intraluminal Support Stent or Pipeline Embolization Device

Peng Lu,Ye Zhang,Huanjiang Niu,Yirong Wang

DOI: https://doi.org/10.3892/etm.2019.7775

IF: 2.7

2019-01-01

Experimental and Therapeutic Medicine

Abstract:The aim of the present study was to evaluate the safety and effectiveness of low-profile visualized intraluminal support (LVIS) stent and the pipeline embolization device (PED) for middle cerebral artery (MCA) aneurysm treatment. Data of patients with MCA aneurysms who received endovascular treatment with LVIS stent or PED added to the hospital's database between August 2016 and March 2018 were retrospectively collected, and the clinical results and angiographic outcomes were evaluated. A total of 43 patients were included in the study, of whom 23 received LVIS stents and 20 received PED. The rate of complete occlusion was similar in the two groups at 6 months post-treatment (90.9 vs. 88.9%; P=0.832). Peri-operative complications were more frequent in the PED group; however, the LVIS group had more ischemic symptoms during the long-term follow-up. A larger aneurysm size (P=0.032) was associated with recanalization in the two groups. In conclusion, the LVIS stent and PED had acceptable rates of complete occlusion and aneurysm size was an independent predictor for recanalization. LVIS is more effective during the peri-operative period, while PED appears to have higher long-term safety.
Angiographic and clinical outcomes from 396 aneurysms treated with the pipeline flex embolization device with shield technology

Ivan Lylyk,Esteban Scrivano,Javier Lundquist,Carlos Bleise,Nicolas Perez,Pedro Nicolas Lylyk,Rodolfo Nella-Castro,Pedro Lylyk

DOI: https://doi.org/10.1177/15910199241231018

IF: 1.7

2024-05-01

Interventional Neuroradiology

Abstract:Interventional Neuroradiology, Ahead of Print. BackgroundThe PEDESTRIAN registry demonstrated high rates of complete long-term occlusion and good clinical outcomes among patients with intracranial aneurysms treated with the pipeline embolization device. The pipeline flex embolization device with shield technology was introduced to minimize thromboembolic complications. In this study, we investigated the safety and effectiveness of pipeline embolization device with shield technology among all patients treated for intracranial aneurysms at our center.MethodsThis was a single-arm retrospective study of prospectively collected data of patients treated with pipeline embolization device with shield technology at our high-volume center between January 2018–January 2021. The primary efficacy endpoint was complete occlusion as measured by a class 1 Raymond-Roy score at 1-year and 2-year follow-up. The primary safety endpoint was major morbidity and neurological mortality up to 1 year following intervention.ResultsA total of 328 patients (mean age 56.1 ± 14.7 years; 81.1% female), 80 of whom were previously included in PEDESTRIAN, with 396 aneurysms, were analyzed. A total of 378 devices were deployed, with 93.9% (372/396) of aneurysms requiring only one device. Follow-up angiography was available for 90.2% (296/328) of the procedures after a mean time of 14.0 ± 8.2 months. Complete occlusion was demonstrated for 78.5% (132/168) of aneurysms at 12 months and 90.7% (98/108) at 24 months. The overall rates of major morbidity and neurological mortality after 2 years were 1.5% (5/328) and 0.6% (2/328), respectively.ConclusionOur results demonstrate high rates of complete long-term occlusion among patients treated with pipeline embolization device with shield technology. We also observed low rates of mortality and morbidity consistent with fewer thromboembolic complications with pipeline embolization devices with shield technology.

radiology, nuclear medicine & medical imaging,clinical neurology
The rifamycins with other drugs in the treatment of pulmonary tuberculosis: a report of nine cases.

A. Pines,H. Raafat,R. Bundi

DOI: https://doi.org/10.1016/S0041-3879(67)80035-7

1967-12-01

Tubercle

Abstract:
Pipeline Vantage Embolization Device for the treatment of intracranial aneurysms: A systematic review and meta-analysis

Lukas Goertz,Sophia Hohenstatt,David Zopfs,Jonathan Kottlors,Lenhard Pennig,Marc Schlamann,Arwed Elias Michael,Thomas Liebig,Markus A. Möhlenbruch,Christoph Kabbasch

DOI: https://doi.org/10.1177/15910199241264340

IF: 1.7

2024-07-27

Interventional Neuroradiology

Abstract:Interventional Neuroradiology, Ahead of Print. ObjectiveThe Pipeline Vantage Embolization Device (PVED) is a novel coated flow diverter with reduced wire diameters to improve neoendothelialization and stent porosity. This systematic review evaluates the safety and efficacy of the PVED based on the current literature.MethodsFollowing the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, a thorough literature search was conducted using PubMed, EMBASE, and Cochrane. The random effects model was used to calculate estimates with major neurological complications within 30 days of treatment as the primary safety endpoint and ≤1-year complete occlusion rate as the primary efficacy endpoint.ResultsSix single-arm studies (5 retrospective, 1 prospective) with 392 patients and 439 aneurysms (6.8% ruptured) were included. Antiplatelet regimens varied, but dual antiplatelet therapy was administered in the majority. The pooled technical success rate was 99.0% (95%CI, 98.0%–100%) with an average of 1.2 devices implanted per procedure. Balloon angioplasty was performed in 17.0% (95%CI, 6.4–27.6%) and adjunctive coiling in 28.0% (95%CI, 17.8–38.2%), with significant heterogeneity for both variables. Pooled estimates for major neurological complications were 3.5% (95%CI, 1.7%–5.2%) with total ischemic events in 4.1% (95% CI, 1.6%–6.6%) and hemorrhagic events in 1.0% (95% CI, 0.0%–1.9%). The rate of complete angiographic occlusion was 75.7% (95%CI, 70.7%–80.6%) at a mean follow-up of 7 months, with in-stent stenoses in 8.1% (95%CI, 4.5%–11.8%).ConclusionsThe safety and efficacy profile of the PVED appears comparable to competing devices, with potentially fewer complications than first-generation flow diverters. Long-term and comparative studies are needed to further confirm these results.

radiology, nuclear medicine & medical imaging,clinical neurology
Vanguard Study: Initial experience with the new fourth generation Pipeline Vantage Flow Diverter (PVFD): 6-month results, technical and clinical considerations

Laetitia de Villiers,Vinicius Carraro do Nascimento,Luis Domitrovic,Permesh Singh Dhillon,Hal Rice

DOI: https://doi.org/10.1136/jnis-2023-021182

IF: 4.8

2024-01-03

Journal of NeuroInterventional Surgery

Abstract:Background The Pipeline Embolization Device has proven to be a safe and effective device for the treatment of intracranial aneurysms. The Pipeline Vantage Flow Diverter (PVFD) with Shield Technology is the new fourth generation of this implant, with modifications made compared to previous iterations. We aimed to evaluate the mechanical properties and clinical safety and efficacy of this device. Methods Vanguard is a single arm, single center, prospective study. Between April 2021 and April 2023, all consecutive patients with an unruptured aneurysm treated with Pipeline Vantage flow-diverting stents were included. There were no aneurysm size or location exclusion criteria. Safety (neurological serious adverse events) and efficacy (device deployment and aneurysm occlusion) were independently reviewed. Imaging follow-up data, and immediate, early ( 30 days) neurological serious adverse events were independently assessed. Results 101 consecutive patients with a total of 115 aneurysms were included. The aneurysms were situated in the anterior (90.4%) or posterior (9.6%) circulations. A total of 124 devices were implanted. The deployment success rate was 100%. In four (4.0%) cases post-deployment angioplasty was required to optimize device wall apposition. Occlusion rates at 1 month were 54.7%, at 3 months 72.1%, and at 6 months 81.7%. Morbidity and mortality were 4.9% and 0%, respectively, at 6 months. Eight cases (6.9%) demonstrated in-stent stenosis, four of which had ‘fish mouth’ deformity. Conclusion Initial results of the new generation PVFD for unruptured intracranial aneurysm treatment demonstrate overall satisfactory device performance, safety profile, and effectiveness.

surgery,neuroimaging
Clinical outcomes of pipeline embolization devices with shield technology for treating intracranial aneurysms

Chao Luo,Lide Jin,Jigen Dong,Zaixiang Fu,Erheng Liu,Shi Yin,Lipeng Jian,Pengren Luo,Bo Liu,Wei Huang,Shuai Zhou

DOI: https://doi.org/10.3389/fneur.2022.971664

IF: 3.4

2022-11-14

Frontiers in Neurology

Abstract:Introduction: As a common endovascular treatment for intracranial aneurysms, the pipeline embolization device (PED) is considered a standard treatment option, especially for large, giant, wide-necked, or dissecting aneurysms. A layer of phosphorylcholine biocompatible polymer added to the surface of the PED can substantially improve this technology. This PED with shield technology (pipeline shield) is relatively novel; its early technical success and safety have been reported. We conducted a systematic literature review with the aim of evaluating the efficacy and safety of the pipeline shield. Methods: We searched the PubMed, Embase, and Cochrane databases, following the preferred reporting items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Results: We selected five prospective and two retrospective studies for review. A total of 572 aneurysms were included; of these, 506 (88.5%) were unruptured. The antiplatelet regimens were heterogeneous. The rate of perioperative and postoperative complications was 11.1% [95% confidence interval (CI): 6.5–18.9%]. The adequate occlusion rate at 6 months was 73.9% (95% CI: 69.1–78.7%). The adequate occlusion rate of more than 12 months was 80.9% (95% CI: 75.1–86.1%). The mortality rate was 0.7% (95% CI: 0.2–1.5%). Subgroup analyses showed that aneurysm rupture status had no effect on aneurysm occlusion rate, patient morbidity, or mortality. Conclusion: This review demonstrates the safety and efficacy of the pipeline shield for treating intracranial aneurysms. However, direct comparisons of the pipeline shield with other flow diverters are needed to better understand the relative safety and effectiveness of different devices.

neurosciences,clinical neurology
Fourth-generation PipelineTM Vantage flow diversion: First reported US experience of safety and feasibility

Ahmad Sweid,Ahmad Chahine,Stephanie Hage,Rami Z Morsi,Sonam Thind,Lina Karar,Archit Baskaran,Julián Carrión-Penagos,Harsh Desai,Sachin A Kothari,Rohini Rana,Okker Verhagen Metman,Jehad Zakaria,James E Siegler,Issam Awad,Michael C Hurley,Shyam Prabhakaran,Sean Polster,Tareq Kass-Hout

DOI: https://doi.org/10.1177/15910199241301119

IF: 1.7

2024-12-06

Interventional Neuroradiology

Abstract:Interventional Neuroradiology, Ahead of Print. BackgroundThe PipelineTM Vantage embolization device (Medtronic, Irvine, CA) is the fourth generation of Pipeline flow diverter devices, offering numerous technical improvements. This study aimed to assess the feasibility and safety of The PipelineTM Vantage embolization device (Medtronic, Irvine, CA).MethodsThis was a single-center retrospective study describing the use of The PipelineTM Vantage embolization device for the treatment of intracranial aneurysms. Technical feasibility and safety were assessed in terms of intra and postprocedural complications, as well as neurological morbidity upon follow-up. Both ruptured and unruptured aneurysms were included.ResultsWe included 12 patients in our study (mean age 62; females: n = 9/12, 75%). Aneurysm morphology varied between saccular (41.6%), fusiform (41.6%), blister (8.3%), and pseudoaneurysm (8.3%). Three cases (25%) involved ruptured aneurysms treated in the acute setting. A transradial access was used in 10 cases (83.3%). There was a 100% success in deployment. Seven cases (58.3%) were treated with adjunct embolization device other than a flow diversion. Eight cases (66.6%) were treated with a single flow diversion, three cases (25%) were treated with two flow diversion, and one case (8.3%) was treated with three flow diversion stents. There were no intraoperative complications. There was one postprocedural complication in a dissecting ruptured PICA aneurysm that was ultimately treated with two flow diversion stents and an intrasaccular device.DiscussionTo our knowledge, this is the first US series assessing the periprocedural safety and feasibility of consecutive patients with intracranial aneurysms treated with the PipelineTM Vantage device (Medtronic, Irvine, CA).

radiology, nuclear medicine & medical imaging,clinical neurology
Complex cerebral aneurysms: intra-luminal reconstruction using Pipeline flow-diverting stent and the obliteration mechanism

Xianli Lv,Chuhan Jiang,Zhongxue Wu,Weijian Jiang,Guihuai Wang

DOI: https://doi.org/10.1177/1971400919894879

2019-12-11

The Neuroradiology Journal

Abstract:Objectives Patients with complex cerebral aneurysms can now be treated intravascularly with the help of flow-diverting stents. The primary purpose of this article is to document the clinical and angiographic outcomes in 80 patients who were treated with the Pipeline flow-diverting stent (PFS; Medtronic, Dublin, Ireland) and the obliteration mechanism was discussed. Patients and methods Between October 2015 and October 2019, 80 patients with 90 complex (undefined neck, large/giant, blood blister–like, and recurrent side-wall) cerebral aneurysms treated with the PFS were retrospectively reviewed. Forty-five patients were women and 35 were men, with a mean age of 52 years. Large or giant aneurysms were defined as 10 mm or larger and small aneurysms were defined as less than 10 mm at the largest diameter measured on angiogram. Results Forty-one aneurysms (45.6%) were large or giant, 41 (45.6%) were small, four (4.4%) were recurrent side-wall aneurysms and four (4.4%) were blood blister–like aneurysms. In total, 87 PFSs were placed in 80 patients with 90 aneurysms. In six patients, coexisting proximal stenosis of parent artery was also covered with PFS without balloon angioplasty. Adjunct coils were placed in 31 aneurysms (34%). One patient died of intracerebral hematoma after thrombolysis. There was one intrastent occlusion at six-month follow-up without any symptoms. The morbidity and the mortality rate is 0% and 1.3% (95% confidence interval (CI), 0%–3.7%). Control angiography was available in 74 (92.5%) patients with 83 aneurysms, and the aneurysm occlusion rate was 98.8% (95% CI, 96.5%–100%) in 6 to 12 months. Conclusion For wide-necked saccular, large/giant, blood blister–like aneurysms and recurrent side-wall aneurysms, PFS is a valid and safe treatment option.
Safety and effect of pipeline flex embolization device for complex unruptured intracranial aneurysms

Shun-Qiang Chen,Li Li,Bu-Lang Gao,Qiao-Wei Wu,Qiu-Ji Shao,Zi-Liang Wang,Kun Zhang,Tian-Xiao Li

DOI: https://doi.org/10.1038/s41598-023-31638-0

IF: 4.6

2023-03-20

Scientific Reports

Abstract:To investigate the safety and short-term effect of Pipeline Flex devices in the treatment of complex unruptured intracranial aneurysms, a retrospective study was performed for patients with complex unruptured intracranial aneurysms who were treated with the Pipeline Flex embolization device (PED Flex device) combined with or without coiling. The clinical, endovascular, and follow-up data were analyzed. One hundred and thirty-one patients with 159 complex unruptured cerebral aneurysms were treated with the PED Flex device, with 144 Flex devices deployed. Periprocedural complications occurred in four patients, resulting in the complication rate of 3.1%, including ischemic complications in three patients (2.3%) and hemorrhagic complication in one (0.8%). At discharge, the mRS was 0 in 101 (77.1%) patients, 1 in 25 (19.1%), 2 in four (3.1%), and 4 in one (0.8%), with the good prognosis rate (mRS 0–2) of 99.2%. Clinical follow-up was carried out in 87 (66.4%) patients 3–42 months after the procedure, with the mRS of 0 in 78 (89.7%), 1 in five (5.7%), 2 in three (3.4%), and 4 in one (1.1%). No significant (P = 0.16) difference existed in the mRS at discharge compared with that at clinical follow-up. Angiographic follow-up was performed in 61 (46.7%) patients with 80 (50.3%) aneurysms at 3–40 months, with the OKM grade of D in 57 (71.3%) aneurysms, C in eight (10%), and B in 15 (18.8%). Asymptomatic instent stenosis occurred in four patients (6.6%). In conclusion: The treatment of complex intracranial aneurysms with the Pipeline Flex embolization device may be safe and effective, with a high complete occlusion rate, a decreased complication rate, and a good prognosis rate at medium follow-up.

multidisciplinary sciences
Predictors of occlusion, long-term outcomes, and safety in a cohort of 674 aneurysms treated with the Pipeline embolization device

Rawad Abbas,Ahmad Sweid,Mohamed M. Salem,Elias Atallah,Kareem El Naamani,Abdelaziz Amllay,Georgios S. Sioutas,Abhijeet Sambangi,Clifford J. Yudkoff,Jaime Dougherty,Joshua H. Weinberg,Jad El-Hajj,Abdulaziz Alhussein,Ruyof Alhussein,Nabeel A. Herial,Stavropoula Tjoumakaris,M. Reid Gooch,Hekmat Zarzour,Richard F. Schmidt,Robert H. Rosenwasser,Pascal Jabbour

DOI: https://doi.org/10.3171/2023.10.jns231837

IF: 5.408

2024-01-01

Journal of Neurosurgery

Abstract:OBJECTIVE By providing a more physiological approach to the treatment of intracranial aneurysms, the Pipeline embolization device (PED) has revolutionized the endovascular treatment of aneurysms. Although there are many flow diverters on the market, the authors report their experience with the PED, the first flow diverter to be approved by the Food and Drug Administration. They aimed to assess the efficacy and safety of PED flow diversion for the treatment of a wide range of aneurysms, as well as to look at factors affecting occlusion. METHODS This is a retrospective study of a prospectively maintained database of patients treated with the PED between January 2011 and December 2019. Charts were reviewed for patient, aneurysm, and procedure characteristics. The primary outcomes of interest were complication rates, occlusion outcomes (O’Kelly-Marotta grading scale), and functional outcomes (modified Rankin Scale [mRS]). Secondary outcomes included predictors of incomplete occlusion at 6 and 24 months of follow-up. RESULTS The study cohort included 581 patients with 674 aneurysms. Most aneurysms (90.5%) were in the anterior circulation and had a saccular morphology (85.6%). Additionally, 638 aneurysms (94.7%) were unruptured, whereas 36 (5.3%) were acutely ruptured. The largest mean aneurysm diameter was 8.3 ± 6.1 mm. Complications occurred at a rate of 5.5% (n = 32). The complete occlusion rate was 89.3% at 24 months’ follow-up, and 94.8% of patients had a favorable neurological outcome (mRS score 0–2) at the last follow-up. On multivariate analysis, predictors of incomplete aneurysm occlusion at 6 months were hypertension (OR 1.7, p = 0.03), previous aneurysm treatment (OR 2.4, p = 0.001), and increasing aneurysm neck diameter (OR 1.2, p = 0.02), whereas a saccular morphology was protective (OR 0.5, p = 0.05). Predictors of incomplete occlusion at 24 months were increasing aneurysm neck diameter (OR 1.2, p = 0.01) and previous aneurysm treatment (OR 2.3, p = 0.01). CONCLUSIONS The study findings are corroborated by those of previous studies and trials. The complete occlusion rate was 89.3% at 24 months’ follow-up, with 94.8% of patients having favorable functional outcomes (mRS score 0–2). Aneurysm treatment before PED deployment and an increasing aneurysm neck diameter increase the risk of incomplete occlusion at 6 and 24 months.

surgery,clinical neurology
Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results

Ricardo A Hanel,David F Kallmes,Demetrius Klee Lopes,Peter Kim Nelson,Adnan Siddiqui,Pascal Jabbour,Vitor M Pereira,Istvan Szikora István,Osama O Zaidat,Chetan Bettegowda,Geoffrey P Colby,Maxim Mokin,Clemens Schirmer,Frank R Hellinger,Curtis Given Ii,Timo Krings,Philipp Taussky,Gabor Toth,Justin F Fraser,Michael Chen,Ryan Priest,Peter Kan,David Fiorella,Don Frei,Beverly Aagaard-Kienitz,Orlando Diaz,Adel M Malek,C Michael Cawley,Ajit S Puri,Curtis Given II

DOI: https://doi.org/10.1136/neurintsurg-2019-015091

IF: 4.8

2019-07-15

Journal of NeuroInterventional Surgery

Abstract:Background Preliminary clinical studies on the safety and efficacy of the pipeline embolization device (PED) for the treatment of small/medium aneurysms have demonstrated high occlusion rates with low complications. Objective To evaluate the safety and effectiveness of the PED for treatment of wide necked small and medium intracranial aneurysms. Methods PREMIER is a prospective, multicenter, single arm trial. Patients were treated with the PED for unruptured wide necked aneurysms, measuring ≤12 mm along the internal carotid artery or vertebral artery, between July 2014 and November 2015. At 1 year post-procedure, the primary effectiveness endpoint was complete occlusion (Raymond grade 1) without major parent vessel stenosis (≤50%) or retreatment, and the primary safety endpoint was major stroke in the territory supplied by the treated artery or neurologic death. Results A total of 141 patients were treated with PEDs (mean age 54.6±11.3 years, 87.9% (124/141) women). Mean aneurysm size was 5.0±1.92 mm, and 84.4% (119/141) measured <7 mm. PED placement was successful in 99.3% (140/141) of patients. Mean number of PEDs implanted per patient was 1.1±0.26; a single PED was used in 92.9% (131/141) of patients. At 1 year, 97.9% (138/141) of patients underwent follow-up angiography with 76.8% (106/138) of patients having met the study’s primary effectiveness endpoint. The combined major morbidity and mortality rate was 2.1% (3/140). Conclusions Treatment of wide necked small/medium aneurysms with the PED results in high rates of complete occlusion without significant parent vessel stenosis and low rates of permanent neurologic complications. Trial registration NCT02186561 .

surgery,neuroimaging
Pipeline Embolization Device for the Treatment of Ruptured Intracerebral Aneurysms: A Multicenter Retrospective Study

Weiying Zhong,Hong Kuang,Ping Zhang,Xinjian Yang,Bin Luo,Aisha Maimaitili,Yuanli Zhao,Donglei Song,Sheng Guan,Hongqi Zhang,Yang Wang,Donghai Wang,Wandong Su,Yunyan Wang

DOI: https://doi.org/10.3389/fneur.2021.675917

IF: 3.4

2021-09-16

Frontiers in Neurology

Abstract:Background and Purpose: The utilization of flow diversion for ruptured intracerebral aneurysms (IAs) is still limited. We aimed to demonstrate our multicenter experience using the pipeline embolization device (PED) for ruptured IAs that were difficult to treat by clipping and coiling. Methods: Thirty-eight patients with ruptured IAs who underwent PED treatment from 2015 to 2020 were retrospectively reviewed. Factors associated with procedure-related stroke (ischemic and hemorrhagic) and clinical and angiography outcomes were analyzed. Results: There were 14 (36.8%) saccular IAs, 12 (31.6%) blister-like IAs, and 12 (31.6%) dissecting IAs. Perforator involvement was noted in 10 (26.3%) IAs. Early PED placement ( ≤ 15 days) and adjunctive coiling treatment were performed in 27 (71.1%) and 22 (57.9%) cases, respectively. The overall rate of stroke-related complications was 31.6% (12/38) (including rates of 10.5% for procedure-related hemorrhagic complications and 15.8% for procedure-related infarction). The mortality rate was 13.2% (5/38), and 84.2% of patients (32/38) had favorable outcomes. Thirty-two (84.2%) patients underwent follow-up angiographic evaluations; of these, 84.4% (27 patients) had complete occlusion and 15.6% had incomplete obliteration. Multivariate analysis revealed that early PED placement was not associated with a high risk of procedure-related stroke or an unfavorable outcome. Adjunctive coiling exhibited an association with procedure-related stroke ( p = 0.073). Procedure-related hemorrhagic complications were significantly associated with an unfavorable outcome ( p = 0.003). Immediate contrast stasis in the venous phase was associated with complete occlusion during follow-up ( p = 0.050). Conclusion: The PED is a feasible and effective treatment to prevent rebleeding and achieve aneurysm occlusion, but it is associated with a substantial risk of periprocedural hemorrhage and ischemic complications in acute ruptured IAs. Therefore, the PED should be used selectively for acutely ruptured IAs. Additionally, adjunctive coiling might increase procedure-related stroke; however, it may reduce aneurysm rebleeding in acutely ruptured IAs. Patients with immediate contrast stasis in the venous phase were more likely to achieve total occlusion. A prospective study with a larger sample size should be performed to verify our results.

neurosciences,clinical neurology
Comparison of PED/PED Flex and PED Shield in the treatment of unruptured intracerebral aneurysms

Kareem El Naamani,Panagiotis Mastorakos,Clifford J Yudkoff,Rawad Abbas,Stavropoula I Tjoumakaris,M Reid Gooch,Nabeel A Herial,Robert H Rosenwasser,Hekmat Zarzour,Richard F Schmidt,Pascal M Jabbour

DOI: https://doi.org/10.3171/2023.7.JNS23981

2023-08-25

Abstract:Objective: The object of this study was to compare the efficacy and safety profile of the Pipeline embolization device (PED)/Pipeline Flex embolization device (PED Flex) with that of the Pipeline Flex embolization device with Shield Technology (PED Shield). After introducing the first-generation PED and the second-generation PED Flex with its updated delivery system, the PED Shield was launched with a synthetic layer of phosphorylcholine surface modification to reduce thrombogenicity. Methods: This is a retrospective review of unruptured aneurysms treated with PED/PED Flex versus PED Shield between 2017 and 2022 at the authors' institution. Patients with ruptured aneurysms, adjunctive treatment, failed flow diverter deployment, and prior treatment of the target aneurysm were excluded. Baseline characteristics were collected for all patients, including age, sex, past medical history (hypertension, hyperlipidemia, diabetes mellitus), smoking status, aneurysm location, and aneurysm dimensions (neck, width, height) and morphology (saccular, nonsaccular). The primary outcome was procedural and periprocedural complication rates. Results: The study cohort comprised 200 patients with 200 aneurysms, including 150 aneurysms treated with the PED/PED Flex and 50 treated with the PED Shield. With respect to intraprocedural and periprocedural complications, length of stay, length of follow-up, and functional outcome at discharge, there was no significant difference between the two cohorts. At the midterm follow-up, the rate of in-stent stenosis (PED/PED Flex: 14.2% vs PED Shield: 14.6%, p = 0.927), aneurysm occlusion (complete occlusion: 79.5% vs 80.5%, respectively; neck remnant: 4.7% vs 12.2%; dome remnant: 15.7% vs 7.3%; p = 0.119), and the need for retreatment (5.3% vs 0%, p = 0.097) were comparable between the two cohorts. Conclusions: This study suggests that, as compared to first- and second-generation PED and PED Flex, the third-generation PED Shield offers similar rates of complications, aneurysm occlusion, and in-stent stenosis at the midterm follow-up.
Management of Intracranial Aneurysms that Do Not Occlude on Initial Follow-up After Treatment With the Pipeline Embolization Device

Michael Young,Alejandro Enriquez-Marulanda,Mira Salih,Max Shutran,Karol Budohoski,Ramesh Grandhi,Philipp Taussky,Christopher S Ogilvy

DOI: https://doi.org/10.1227/neu.0000000000002655

IF: 5.315

2024-02-01

Neurosurgery

Abstract:Background and objectives: The pipeline embolization device (PED) has become widely accepted as a safe and efficacious treatment for intracranial aneurysms with high rates of complete occlusion at initial follow-up. For aneurysms that are not completely occluded at initial follow-up, further treatment decision-making is varied. Furthermore, the risk of aneurysmal rupture in these incompletely occluded aneurysms after PED is not known. The objective of this study was to determine treatment decision-making that results in increased occlusion status at final follow-up and to evaluate risk of rupture in those aneurysms that do not go onto occlusion. Methods: This study is a retrospective review of prospective data for intracranial aneurysms treated with PED at two institutions from 2013 to 2019. Aneurysms with near-complete or incomplete occlusion at initial follow-up were included in the statistical analysis. Results: There were 606 total aneurysms treated at two academic institutions with PED with incomplete occlusion at initial follow-up in 134 aneurysms (22.1%). Of the 134 aneurysms that were nonoccluded at initial follow-up, 76 aneurysms (56.7%) went on to complete or near complete occlusion with final complete or near complete occlusion in 90.4% of all aneurysms treated. The time to final imaging follow-up was 28.2 months (13.8-44.3) Retreatment with a second flow diverter was used in 28 aneurysms (20.9%). No aneurysms that were incompletely occluded at initial follow-up had delayed rupture. Furthermore, older patient age was statistically significant for incomplete occlusion at initial follow-up ( P = .05). Conclusion: Intracranial aneurysms treated with the PED that do not occlude at initial follow-up may go on to complete occlusion with continuous observation, alteration in antiplatelet regimens, or repeat treatment. Delayed aneurysmal rupture was not seen in patients with incomplete occlusion.
Multiple Pipeline Embolization Devices for the Treatment of Complex Intracranial Aneurysm: A Multi-Center Study

Feng Fan,Yu Fu,Jianmin Liu,Xinjian Yang,Hongqi Zhang,Tianxiao Li,Huaizhang Shi,Jieqing Wan,Yuanli Zhao,Yunyan Wang,Wenfeng Feng,Donglei Song,Yang Wang,Guohua Mao,Aisha Maimaitili,Sheng Guan

DOI: https://doi.org/10.3389/fnagi.2022.905224

IF: 4.8

2022-01-01

Frontiers in Aging Neuroscience

Abstract:Background The Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial primarily demonstrated the safety and efficacy of the implantation of multiple pipeline embolization devices (multi-PEDs) for large/giant intracranial aneurysms. However, no study has focused on when, why, or how to apply multi-PEDs. Objective The purpose of this study was to investigate the indications and strategies of using multi-PEDs for complex intracranial aneurysms. Methods Patients who had been treated with two or more PEDs were included in the post-market multicenter registry study from 2014 to 2019, across 14 centers in China. Indications, strategies, perioperative safety, and clinical outcomes were retrospectively analyzed. The modified Rankin scale (mRS) score was used to evaluate clinical outcomes comprehensively, and the O’Kelly–Marotta (OKM) grading scale was used to evaluate aneurysm healing results. Results A total of 55 intracranial aneurysms were treated with multi-PEDs. There were 20 fusiform aneurysms with a large range, 25 large/giant saccular aneurysms, six aneurysms with failed treatment, and four aneurysms with greatly varied diameters of the parent artery. The strategies included telescope techniques in 40 patients and overlap techniques in 15 patients. In total, 120 stents were deployed in 55 patients. The operation styles included 25 patients (55.6%) with two PEDs, 21 patients (38.2%) with two PEDs combined with coiling, four patients (7.3%) with three PEDs, four patients (7.3%) with three PEDs combined with coiling, and one patient (1.8%) with four PEDs. Angiography revealed OKM D in two, OKM C in seven, and OKM A and B in 46 cases after surgery. During the perioperative period, eight patients developed neurological dysfunction, three of whom died. A total of thirty-four patients were followed up with digital subtraction angiography for 2–45 (8.2 ± 8.0) months. Angiography revealed OKM D in 26, OKM C in five, and OKM B in three. At the last follow-up, the mRS score was 0–1 in 52 patients. Conclusion The treatment of anterior circulation aneurysms with multi-PEDs is safe and effective. The implantation of multi-PEDs could be considered for large-scale fusiform aneurysms, large/giant saccular aneurysms with a jet-sign, salvage of failed PED treatments, and in cases where the diameter of the parent artery varies greatly.
Treatment of fusiform aneurysms with a pipeline embolization device: a multicenter cohort study

Mirzat Turhon,Huibin Kang,Mengxing Li,Jian Liu,Yisen Zhang,Ying Zhang,Jiliang Huang,Bin Luo,Jianmin Liu,Hongqi Zhang,Tianxiao Li,Donglei Song,Yuanli Zhao,Sheng Guan,Axir Aximujiang,Aisha Maimaitili,Yunyan Wang,Wenfeng Feng,Yang Wang,Jieqing Wan,Guohua Mao,Huaizhang Shi,Xiaolong Zhang,Yuxiang Gu,Xinjian Yang

DOI: https://doi.org/10.1136/neurintsurg-2021-018539

IF: 4.8

2022-03-30

Journal of NeuroInterventional Surgery

Abstract:Background Intracranial fusiform aneurysms are less common than saccular aneurysms, but are associated with higher mortality and morbidity. We conducted this study to determine the safety and efficacy of the pipeline embolization device (PED) to treat intracranial fusiform aneurysms. Methods This was a multicenter, retrospective, and observational study. Data for this study came from the PLUS study conducted from 2014 to 2019 across 14 centers in China. Univariate and multivariable logistic regression analyses were performed to evaluate predictors of the occlusion rate and complication. Results A total of 1171 consecutive patients with 1322 intracranial aneurysms participated in this study. Among the participants, 104 patients with 109 fusiform aneurysms were eligible for this analysis (mean age 49 years, 36.5% women, aneurysm mean size 14.7 mm, 55% in the posterior circulation, and 6% in the basilar artery). Mean follow-up time was 9.0 months (range 3–36 months). The last DSA angiographic follow-up was available for 85 patients, and 58 aneurysms (68.2%) were completely occluded. The overall complication rate and mortality were 17.3% and 2.8%, respectively. Multivariate analysis demonstrated that age (OR=1.007, p=0.037) and cerebral atherosclerosis (OR=1.441, p=0.002) were associated with incomplete occlusion of fusiform aneurysms after PED treatment. Conclusion PEDs may be an effective treatment for intracranial fusiform aneurysms, with a favorable occlusion rate. However, because these treatments have a relatively high rate of complications, PED treatment for fusiform aneurysms should be carefully and strictly controlled. Our analysis showed that PEDs with adjunctive coiling did not significantly improve the occlusion rate of fusiform aneurysms.

surgery,neuroimaging
Safety and efficacy of the pipeline embolization device for treatment of small vs. large aneurysms: a systematic review and meta-analysis

Abdul Karim Ghaith,Elena Greco,Jorge Rios-Zermeno,Victor Gabriel El-Hajj,Carlos Perez-Vega,Marc Ghanem,Samir Kashyap,W Christopher Fox,Thien J Huynh,Sukhwinder S Sandhu,Marcus Ohlsson,Adrian Elmi-Terander,Bernard R Bendok,Mohamad Bydon,Rabih G Tawk

DOI: https://doi.org/10.1007/s10143-023-02192-0

2023-10-26

Abstract:Flow diversion with the pipeline embolization device (PED) is increasingly used to treat intracranial aneurysms with high obliteration rates and low morbidity. However, long-term (≥ 1 year) angiographic and clinical outcomes still require further investigation. The aim of this study was to compare the occlusion and complication rates for small (< 10 mm) versus large (10-25 mm) aneurysms at long-term following treatment with PED. A systematic review and meta-analysis were performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. We conducted a comprehensive search of English language databases including Ovid MEDLINE and Epub Ahead of Print, In-Process, and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Our studies included a minimum of 10 patients treated with PED for small vs. large aneurysms and with at least 12 months of follow-up. The primary safety endpoint was the rate of clinical complications measured by the occurrence of symptomatic stroke (confirmed clinically and radiographically), intracranial hemorrhage, or aneurysmal rupture. The primary efficacy endpoint was the complete aneurysm occlusion rate. Our analysis included 19 studies with 1277 patients and 1493 aneurysms. Of those, 1378 aneurysms met our inclusion criteria. The mean age was 53.9 years, and most aneurysms were small (89.75%; N = 1340) in women (79.1%; N = 1010). The long-term occlusion rate was 73% (95%, CI 65 to 80%) in small compared to 84% (95%, CI 76 to 90%) in large aneurysms (p < 0.01). The symptomatic thromboembolic complication rate was 5% (95%, CI 3 to 9%) in small compared to 7% (95%, CI 4 to 13%) in large aneurysms (p = 0.01). The rupture rate was 2% vs. 4% (p = 0.92), and the rate of intracranial hemorrhage was 2% vs. 4% (p = 0.96) for small vs. large aneurysms, respectively; however, these differences were not statistically significant. The long-term occlusion rate after PED treatment is higher in large vs. small aneurysms. Symptomatic thromboembolic rates with stroke are also higher in large vs. small aneurysms. The difference in the rates of aneurysm rupture and intracranial hemorrhage was insignificant. Although the PED seems a safe and effective treatment for small and large aneurysms, further studies are required to clarify how occlusion rate and morbidity are affected by aneurysm size.
A Study on the Efficacy and Safety of Pipeline Shield Stents and Non-Modified Surface Flow-Diverting Stents in patients with Intracranial Aneurysms

Julio García-Núñez,Daniela D. Vera,Andrés F. Ortiz,Adriana Rodríguez,Juan José Lara,María José Gomez,Sergio Serrano-Gómez,Adriana Reyes,Carlos Ferreira-Prada,Melquizidel Galvis-Méndez,Oliverio Vargas-Pérez,Daniel E. Mantilla-García

DOI: https://doi.org/10.1016/j.wneu.2024.01.028

IF: 2.21

2024-01-13

World Neurosurgery

Abstract:Introduction Few studies have compared the Pipeline Shield stents with previous generations of flow-diverting stents (FDs) for treating unruptured intracranial aneurysms (UIA). This study aimed to evaluate the efficacy and safety of Pipeline Shield stents and FDs without modified surfaces. Materials and Methods The present evaluation is a retrospective cohort study of patients endovascularly treated with Pipeline Shield stents or flow-diverting (FD) stents without modified surfaces for UIA between January 2014 and June 2022. The data analyzed was obtained from the anonymized database of the institution's Interventional Radiology service. Results 147 patients with 155 UIA were included. 96 of them were treated with Pipeline Shield stents and 59 with FDs without modified surfaces. The aneurysms treated with Pipeline Shield stents had higher six-month (OKM D; 87.5 % vs. 71.4 %, p-value: 0.025) and one-year (OKM D; 82.5 % vs. 63.0 %, p-value: 0.047) occlusion rates than aneurysms treated using FDs without modified surfaces. No differences between the devices were found at the one-year follow-up in ischemic stroke (p-value: 0.939) and hemorrhagic complications (p-value: 0.559). Conclusion Pipeline Shield stents demonstrated superior complete occlusion rates (OKM D) at both the six-month and one-year follow-up assessments when compared to non-modified surface FDs. There were no significant differences in the safety profiles between the two types of stents with regard to thromboembolic complications and ischemic events. Further research with larger study populations is necessary to validate these findings.

surgery,clinical neurology
Safety and efficacy of coated flow diverters in the treatment of cerebral aneurysms during single antiplatelet therapy: A multicenter study

Lukas Goertz,Sophia Hohenstatt,Dominik F. Vollherbst,Charlotte S. Weyland,Omid Nikoubashman,Christian Gronemann,Muriel Pflaeging,Eberhard Siebert,Georg Bohner,David Zopfs,Marc Schlamann,Thomas Liebig,Franziska Dorn,Martin Wiesmann,Markus A. Möhlenbruch,Christoph Kabbasch

DOI: https://doi.org/10.1177/15910199241286542

IF: 1.7

2024-10-04

Interventional Neuroradiology

Abstract:Interventional Neuroradiology, Ahead of Print. ObjectiveThis multicenter study evaluates the safety and efficacy of coated flow diverters (cFDs) for the treatment of cerebral aneurysms under single antiplatelet therapy (SAPT).MethodsThis is a retrospective, observational study of 41 patients (median age: 58 years) with 41 aneurysms (median size: 7 mm, 29 [71%] saccular, 9 [22%] ruptured) treated with cFDs at four neurovascular centers between 2020 and 2023. Scheduled cases received continuous SAPT starting seven days before the procedure. Emergency cases were treated with tirofiban followed by SAPT loading. The safety endpoint was ischemic complications occurring during the procedure and within four months of clinical follow-up.ResultsThe Pipeline Vantage or Flex Shield was used in 26 (63%) procedures, the FRED X in 12 (29%), the p48/64 Hydrophilic Polymer Coating in 2 (5%), and the Derivo Embolization Device 2heal in 1 (2%). Single antiplatelet therapy consisted of prasugrel in 27 (66%) patients, ticagrelor in 9 (22%), and ASA in 5 (12%). There were 2 (5%) early ischemic complications (one minor stroke and one transient ischemic attack). There were no late ischemic complications in the four-month follow-up of 35 patients. The six dropouts included four nontreatment-related deaths after subarachnoid hemorrhage and two patients with a poor outcome after subarachnoid hemorrhage. Complete and favorable occlusion rates (median: 7 months) were 75% (27/36) and 89% (32/36), respectively.ConclusionsCoated flow diverter implantation in the setting of SAPT was safe and effective and warrants confirmation in a prospective comparative trial.

radiology, nuclear medicine & medical imaging,clinical neurology
Early Termination versus Standard Regimen Duration of Dual Antiplatelet Therapy in Intracranial Aneurysm Patients Treated With Pipeline Embolization Device Flex With Shield Technology: Preliminary Experience of 3 U.S. Centers

Jaims Lim,Andre Monteiro,Gustavo M Cortez,Victor H Benalia,Ammad A Baig,Wady T Jacoby,Brianna M Donnelly,Bennett R Levy,Vinay Jaikumar,Jason M Davies,Kenneth V Snyder,Adnan H Siddiqui,Ricardo A Hanel,Elad I Levy,Kunal Vakharia

DOI: https://doi.org/10.1016/j.wneu.2023.07.101

Abstract:Background: Pipeline Flex Embolization Device with Shield Technology (PED-Shield) is a third-generation flow diverter with reduced thromboembolic potential. However, safety profile and dual antiplatelet therapy (DAPT) recommendations with PED-Shield is not well -established. We aim to assess the safety and complication profile with early termination of DAPT with use of PED-Shield. Methods: Databases of 3 high-volume cerebrovascular centers were retrospectively reviewed. We identified patients with unruptured and ruptured intracranial aneurysms treated with PED-Shield. Patient demographics, aneurysm characteristics, complications, and angiographic outcomes were extracted. All patients who had early termination of DAPT, defined as <180 days, as well as standard duration were included. Results: A total of 37 patients, totaling 37 aneurysms, had early termination of DAPT and 24 patients with 24 aneurysms received standard duration (>180 days) of DAPT. There was no difference in pre-procedural DAPT regimens between the groups (P = 0.503). Following DAPT termination, o1ne major thromboembolic complication was observed in the early termination group while no major or minor thromboembolic or hemorrhagic complication was noted in the standard duration group. Time of angiographic follow-up was not statistically different (P = 0.063) between the early termination (343 days, interquartile range [IQR] 114-371 days) and the standard duration (175 days, IQR 111-224.5 days) groups. There were no statistically significant differences in complete aneurysm occlusion (P = 0.857), residual neck (P = 0.582), and aneurysm remnant (P = 0.352) rates between the groups on angiography. Conclusions: Early termination of DAPT proves safe after PED-Shield treatment of intracranial aneurysms with comparable complete occlusion rates.

Molybdenum Requirement of Leguminous Plants Supplied with Fixed Nitrogen.

Comparison of Endovascular Treatment for Middle Cerebral Artery Aneurysm with a Low-Profile Visualized Intraluminal Support Stent or Pipeline Embolization Device

Angiographic and clinical outcomes from 396 aneurysms treated with the pipeline flex embolization device with shield technology

The rifamycins with other drugs in the treatment of pulmonary tuberculosis: a report of nine cases.

Pipeline Vantage Embolization Device for the treatment of intracranial aneurysms: A systematic review and meta-analysis

Vanguard Study: Initial experience with the new fourth generation Pipeline Vantage Flow Diverter (PVFD): 6-month results, technical and clinical considerations

Clinical outcomes of pipeline embolization devices with shield technology for treating intracranial aneurysms

Fourth-generation PipelineTM Vantage flow diversion: First reported US experience of safety and feasibility

Complex cerebral aneurysms: intra-luminal reconstruction using Pipeline flow-diverting stent and the obliteration mechanism

Safety and effect of pipeline flex embolization device for complex unruptured intracranial aneurysms

Predictors of occlusion, long-term outcomes, and safety in a cohort of 674 aneurysms treated with the Pipeline embolization device

Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results

Pipeline Embolization Device for the Treatment of Ruptured Intracerebral Aneurysms: A Multicenter Retrospective Study

Comparison of PED/PED Flex and PED Shield in the treatment of unruptured intracerebral aneurysms

Management of Intracranial Aneurysms that Do Not Occlude on Initial Follow-up After Treatment With the Pipeline Embolization Device

Multiple Pipeline Embolization Devices for the Treatment of Complex Intracranial Aneurysm: A Multi-Center Study

Treatment of fusiform aneurysms with a pipeline embolization device: a multicenter cohort study

Safety and efficacy of the pipeline embolization device for treatment of small vs. large aneurysms: a systematic review and meta-analysis

A Study on the Efficacy and Safety of Pipeline Shield Stents and Non-Modified Surface Flow-Diverting Stents in patients with Intracranial Aneurysms

Safety and efficacy of coated flow diverters in the treatment of cerebral aneurysms during single antiplatelet therapy: A multicenter study

Early Termination versus Standard Regimen Duration of Dual Antiplatelet Therapy in Intracranial Aneurysm Patients Treated With Pipeline Embolization Device Flex With Shield Technology: Preliminary Experience of 3 U.S. Centers